Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Makaleler > Tam Makale · 2014
Yazarlar: Edward B. GARON, Tudor-Eliade CİULEANU, Oscar ARRİETA, Kumar PRABHASH, Konstantinos N. SYRIGOS, Tuncay GÖKSEL, Keunchil PARK, Vera GORBUNOVA, Ruben DARIO KOWALYSZYN, Joanna PİKİEL, Grzegorz CZYZEWICZ, Sergey V. ORLOV, Conrad R. LEWANSKI, Michael THOMAS, Paolo BIDOLI, Shaker DAKHIL, Steven GANS, Joo-Hang KIM, Alexandru GRIGORESCU, Nina KARASEVA, Martin RECK, Federico CAPPUZZO, Ekaterine ALEXANDRİS, Andreas SASHEGYI, Sergey YURASOV, Maurice PEROL
The Lancet, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2014, cilt 384, ss 665-673
DOI: 10.1016/s0140-6736(14)60845-x
Özet
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.